Indian Journal of Pharmacology Home 

[View FULLTEXT] [Download PDF]
Year : 2011  |  Volume : 43  |  Issue : 5  |  Page : 492--501

Inverse agonism and its therapeutic significance

Gurudas Khilnani1, Ajeet Kumar Khilnani2 
1 Department of Pharmacology, RNT Medical College, Udaipur, India
2 Department of ENT, JLN Medical College Hospital, Ajmer, Rajasthan, India

Correspondence Address:
Gurudas Khilnani
Department of Pharmacology, RNT Medical College, Udaipur

A large number of G-protein-coupled receptors (GPCRs) show varying degrees of basal or constitutive activity. This constitutive activity is usually minimal in natural receptors but is markedly observed in wild type and mutated (naturally or induced) receptors. According to conventional two-state drug receptor interaction model, binding of a ligand may initiate activity (agonist with varying degrees of positive intrinsic activity) or prevent the effect of an agonist (antagonist with zero intrinsic activity). Inverse agonists bind with the constitutively active receptors, stabilize them, and thus reduce the activity (negative intrinsic activity). Receptors of many classes (α-and β-adrenergic, histaminergic, GABAergic, serotoninergic, opiate, and angiotensin receptors) have shown basal activity in suitable in vitro models. Several drugs that have been conventionally classified as antagonists (β-blockers, antihistaminics) have shown inverse agonist effects on corresponding constitutively active receptors. Nearly all H 1 and H 2 antihistaminics (antagonists) have been shown to be inverse agonists. Among the β-blockers, carvedilol and bucindolol demonstrate low level of inverse agonism as compared to propranolol and nadolol. Several antipsychotic drugs (D 2 receptors antagonist), antihypertensive (AT 1 receptor antagonists), antiserotoninergic drugs and opioid antagonists have significant inverse agonistic activity that contributes partly or wholly to their therapeutic value. Inverse agonism may also help explain the underlying mechanism of beneficial effects of carvedilol in congestive failure, naloxone-induced withdrawal syndrome in opioid dependence, clozapine in psychosis, and candesartan in cardiac hypertrophy. Understanding inverse agonisms has paved a way for newer drug development. It is now possible to develop agents, which have only desired therapeutic value and are devoid of unwanted adverse effect. Pimavanserin (ACP-103), a highly selective 5-HT 2A inverse agonist, attenuates psychosis in patients with Parkinson«SQ»s disease with psychosis and is devoid of extrapyramidal side effects. This dissociation is also evident from the development of anxioselective benzodiazepines devoid of habit-forming potential. Hemopressin is a peptide ligand that acts as an antagonist as well as inverse agonist. This agent acts as an antinociceptive agent in different in vivo models of pain. Treatment of obesity by drugs having inverse agonist activity at CB 1/2 receptors is also underway. An exciting development is evaluation of β-blockers in chronic bronchial asthma-a condition akin to congestive heart failure where β-blockade has become the standard mode of therapy. Synthesis and evaluation of selective agents is underway. Therefore, inverse agonism is an important aspect of drug-receptor interaction and has immense untapped therapeutic potential.

How to cite this article:
Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance.Indian J Pharmacol 2011;43:492-501

How to cite this URL:
Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian J Pharmacol [serial online] 2011 [cited 2023 Sep 25 ];43:492-501
Available from:;year=2011;volume=43;issue=5;spage=492;epage=501;aulast=Khilnani;type=0